Kura Oncology, Inc. $KURA Stock Sold by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. cut its position in Kura Oncology, Inc. (NASDAQ:KURA) by 36.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,174,880 shares of the company’s stock after selling 667,470 shares during the period. Nan Fung Trinity HK Ltd. owned 1.32% of Kura Oncology worth $12,583,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in KURA. IFP Advisors Inc raised its stake in Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after buying an additional 1,467 shares during the period. Sterling Capital Management LLC boosted its holdings in Kura Oncology by 842.5% in the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock worth $30,000 after acquiring an additional 2,519 shares in the last quarter. Physician Wealth Advisors Inc. bought a new position in Kura Oncology in the third quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kura Oncology in the third quarter valued at approximately $49,000. Finally, Allworth Financial LP acquired a new stake in Kura Oncology in the second quarter valued at approximately $113,000.

Analysts Set New Price Targets

Several research firms have recently commented on KURA. Wedbush boosted their price objective on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, October 14th. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, October 15th. Finally, Citizens Jmp restated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.88.

Kura Oncology Price Performance

KURA opened at $7.43 on Friday. The company has a quick ratio of 4.71, a current ratio of 3.60 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average price is $10.28 and its two-hundred day moving average price is $9.77. Kura Oncology, Inc. has a 1 year low of $6.75 and a 1 year high of $13.90.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The company had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million. On average, equities analysts anticipate that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Insiders Place Their Bets

In other Kura Oncology news, insider Teresa Bair sold 8,442 shares of the stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.50, for a total value of $88,641.00. Following the completion of the sale, the insider owned 187,002 shares in the company, valued at approximately $1,963,521. This trade represents a 4.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Thomas Doyle sold 4,607 shares of Kura Oncology stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.50, for a total transaction of $48,373.50. Following the transaction, the senior vice president directly owned 142,428 shares in the company, valued at approximately $1,495,494. This represents a 3.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 153,881 shares of company stock worth $1,708,183 in the last ninety days. 7.60% of the stock is owned by corporate insiders.

Kura Oncology Company Profile

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.